Cited by 2,292Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction ResearchCancer, Lipids, and Metabolism

The DOI matches its Crossref record, with a small difference in title or year; 28 of the 28 references it cites were found in a registry or an index.

C-Reactive Protein Levels and Outcomes after Statin Therapy

Open access

Ridker, Paul M, Cannon, Christopher P., Morrow, David, Rifai, Nader, Rose, Lynda M., McCabe, Carolyn H., Pfeffer, Marc A., Braunwald, Eugene·2005·New England Journal of Medicine

DOI 10.1056/nejmoa042378

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Statins lower the levels of low-density lipoprotein (LDL) cholesterol and C-reactive protein (CRP). Whether this latter property affects clinical outcomes is unknown. METHODS: We evaluated relationships between the LDL cholesterol and CRP levels achieved after treatment with 80 mg of atorvastatin or 40 mg of pravastatin per day and the risk of recurrent myocardial infarction or death from coronary causes among 3745 patients with acute coronary syndromes. RESULTS: Patients in whom statin therapy resulted in LDL cholesterol levels of less than 70 mg per deciliter (1.8 mmol per liter) had lower event rates than those with higher levels (2.7 vs. 4.0 events per 100 person-years, P=0.008). However, a virtually identical difference was observed between those who had CRP levels of less than 2 mg per liter after statin therapy and those who had higher levels (2.8 vs. 3.9 events per 100 person-years, P=0.006), an effect present at all levels of LDL cholesterol achieved. For patients with post-treatment LDL cholesterol levels of more than 70 mg per deciliter, the rates of recurrent events were 4.6 per 100 person-years among those with CRP levels of more than 2 mg per liter and 3.2 events per 100 person-years among those with CRP levels of less than 2 mg per liter; the respective rates among those with LDL cholesterol levels of less than 70 mg per deciliter were 3.1 and 2.4 events per 100 person-years (P<0.001). Although atorvastatin was more likely than pravastatin to result in low levels of LDL cholesterol and CRP, meeting these targets was more important in determining the outcomes than was the specific choice of therapy. Patients who had LDL cholesterol levels of less than 70 mg per deciliter and CRP levels of less than 1 mg per liter after statin therapy had the lowest rate of recurrent events (1.9 per 100 person-years). CONCLUSIONS: Patients who have low CRP levels after statin therapy have better clinical outcomes than those with higher CRP levels, regardless of the resultant level of LDL cholesterol. Strategies to lower cardiovascular risk with statins should include monitoring CRP as well as cholesterol.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa042378

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Inflammation in atherosclerosis
Libby, P. (2002) · Nature · doi:10.1038/nature01323 · Cited by 8,315
Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
Ridker, P. M., Cushman, M., Stampfer, M. J., Tracy, R. P., & Hennekens, C. H. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704033361401 · Cited by 5,504
Self-citation
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Self-citation
Comparison of C-Reactive Protein and Low-Density Lipoprotein Cholesterol Levels in the Prediction of First Cardiovascular Events
Ridker, P. M., Rifai, N., Rose, L., Buring, J. E., & Cook, N. R. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021993 · Cited by 3,604
Self-citation
C-Reactive Protein and Other Circulating Markers of Inflammation in the Prediction of Coronary Heart Disease
Danesh, J., Wheeler, J. G., Hirschfield, G. M., Eda, S., Eiriksdottir, G., Rumley, A., Lowe, G. D. O., Pepys, M. B., & Gudnason, V. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032804 · Cited by 2,953
The Prognostic Value of C-Reactive Protein and Serum Amyloid A Protein in Severe Unstable Angina
Liuzzo, G., Biasucci, L. M., Gallimore, J. R., Grillo, R. L., Rebuzzi, A. G., Pepys, M. B., & Maseri, A. (1994) · New England Journal of Medicine · doi:10.1056/nejm199408183310701 · Cited by 2,354
Effect of Statin Therapy on C-Reactive Protein Levels
Albert, M. A., Danielson, E., Rifai, N., Ridker, P. M., & for the PRINCE Investigators (2001) · JAMA · doi:10.1001/jama.286.1.64 · Cited by 1,644
Self-citation
Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events
Ridker, P. M., Rifai, N., Clearfield, M., Downs, J. R., Weis, S. E., Miles, J. S., & Gotto, A. M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106283442601 · Cited by 1,557
Self-citation

Flagged first, then by citations

Show all 28 references

Research works printed but not linked: 1

Davignon J, 2004, Circulation, 109, III

Sorted by citations

Items 401–500 of 1,000

C-reactive protein and atherogenesis: From fatty streak to clinical event
Bisoendial, R. J., Kastelein, J. J. P., & Stroes, E. S. G. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.04.053 · Cited by 95
Statins inhibit C-reactive protein-induced chemokine secretion, ICAM-1 upregulation and chemotaxis in adherent human monocytes
Montecucco, F., Burger, F., Pelli, G., Poku, N. K., Berlier, C., Steffens, S., & Mach, F. (2009) · Lara D. Veeken · doi:10.1093/rheumatology/ken466 · Cited by 96
Effects of Atorvastatin on Inflammatory and Fibrinolytic Parameters in Patients with Chronic Kidney Disease
Goicoechea, M., de Vinuesa, S. G., Lahera, V., Cachofeiro, V., Gómez-Campderá, F. J., Vega, A., Abad, S., & Luño, J. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006080938 · Cited by 97
Impact of better adherence to statin agents in the primary prevention of coronary artery disease
Perreault, S., Dragomir, A., Blais, L., Bérard, A., Lalonde, L., White, M., & Pilon, D. (2009) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-009-0673-0 · Cited by 96
Cardiac biomarkers: a contemporary status report
Maisel, A. S., Bhalla, V., & D, E. B. M. (2006) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio0405 · Cited by 95
C-Reactive Protein Increase in Unstable Coronary Disease
Servi, S. D., Mariani, M., Mariani, G., & Mazzone, A. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.05.083 · Cited by 95
Statin use in patients with asthma - a nationwide population-based study
Huang, C., Chan, W., Chen, Y., Chen, T., Chou, K., Lin, S., Chen, J., & Leu, H. (2010) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2010.02434.x · Cited by 94
Oral rapamycin attenuates inflammation and enhances stability of atherosclerotic plaques in rabbits independent of serum lipid levels
Chen, W. Q., Zhong, L., Zhang, L., Ji, X. P., Zhang, M., Zhao, Y. X., Zhang, C., & Zhang, Y. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2008.00102.x · Cited by 93
High Serum C-Reactive Protein Level Is Not an Independent Predictor for Stroke
Bos, M. J., Schipper, C. M. A., Koudstaal, P. J., Witteman, J. C. M., Albert Hofman, D., & Breteler, M. M. B. (2006) · Circulation · doi:10.1161/circulationaha.106.619833 · Cited by 93
Inflammatory Trajectory of Type 2 Diabetes: Novel Opportunities for Early and Late Treatment
Pellegrini, V., Grotta, R. L., Carreras, F., Giuliani, A., Sabbatinelli, J., Olivieri, F., Berra, C., Ceriello, A., & Prattichizzo, F. (2024) · Cells · doi:10.3390/cells13191662 · Cited by 105
Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: Results of the CAP (Comparative Atorvastatin Pleiotropic effects) study
Bonnet, J., McPherson, R., Tedgui, A., Simoneau, D., Nozza, A., Martineau, P., & Davignon, J. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.12.023 · Cited by 92
Combination of bempedoic acid, ezetimibe, and atorvastatin in patients with hypercholesterolemia: A randomized clinical trial
Rubino, J., MacDougall, D. E., Sterling, L. R., Hanselman, J. C., & Nicholls, S. J. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.12.023 · Cited by 96
Long-Term Cardiovascular Effects of COVID-19: Emerging Data Relevant to the Cardiovascular Clinician
Tobler, D. L., Pruzansky, A. J., Naderi, S., Ambrosy, A. P., & Slade, J. J. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01032-8 · Cited by 98
Statins, inflammation and kidney disease
Krane, V., & Wanner, C. (2011) · Nature Reviews Nephrology · doi:10.1038/nrneph.2011.62 · Cited by 89
Traditional Chinese medication Tongxinluo dose-dependently enhances stability of vulnerable plaques: a comparison with a high-dose simvastatin therapy
Zhang, L., Liu, Y., Lu, X. T., Wu, Y. L., Zhang, C., Ji, X. P., Wang, R., Liu, C. X., Feng, J. B., Jiang, H., et al. (2009) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00208.2009 · Cited by 90
Magnesium and C-reactive protein in heart failure: an anti-inflammatory effect of magnesium administration?
Almoznino‐Sarafian, D., Berman, S., Mor, A., Shteinshnaider, M., Gorelik, O., Tzur, I., Alon, I., Modai, D., & Cohen, N. (2007) · European Journal of Nutrition · doi:10.1007/s00394-007-0655-x · Cited by 91
Pooled Analyses of Effects on C-Reactive Protein and Low Density Lipoprotein Cholesterol in Placebo-Controlled Trials of Ezetimibe Monotherapy or Ezetimibe Added to Baseline Statin Therapy
Pearson, T. A., Ballantyne, C. M., Veltri, E. P., Shah, A. K., Bird, S. R., Lin, J., Rosenberg, E., & Tershakovec, A. M. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.09.090 · Cited by 91
Endothelial Nitric Oxide Synthase
Rabelink, T. J., & Lüscher, T. F. (2005) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000196554.85799.77 · Cited by 92
Intracoronary Imaging, Cholesterol Efflux, and Transcriptomes After Intensive Statin Treatment
Kini, A. S., Vengrenyuk, Y., Shameer, K., Maehara, A., Meerarani, P., Yoshimura, T., Matsumura, M., Aquino, M. B., Haider, N., Johnson, K. W., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.10.029 · Cited by 92
Lipoprotein-Associated Phospholipase A2: An Independent Predictor of Coronary Artery Disease Events in Primary and Secondary Prevention
Anderson, J. L. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.04.015 · Cited by 89
Therapy with angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and statins: No effect on ablation outcome after ablation of atrial fibrillation
Richter, B., Derntl, M., Marx, M., Lercher, P., & Gössinger, H. (2006) · American Heart Journal · doi:10.1016/j.ahj.2006.09.006 · Cited by 91
High-sensitivity C-reactive protein as a biomarker of risk in coronary artery disease
Silva, D., & de Lacerda, A. P. (2012) · Revista Portuguesa de Cardiologia (English Edition) · doi:10.1016/j.repce.2012.09.006 · Cited by 90
Cellular and molecular mechanisms of statins: an update on pleiotropic effects
Satoh, M., Takahashi, Y., Tabuchi, T., Minami, Y., Tamada, M., Takahashi, K., Itoh, T., Morino, Y., & Nakamura, M. (2015) · Clinical Science · doi:10.1042/cs20150027 · Cited by 92
High-Sensitivity C-Reactive Protein Is Associated With Incident Type 2 Diabetes Among African Americans: The Jackson Heart Study
Effoe, V. S., Correa, A., Chen, H., LACY, M. E., & Bertoni, A. G. (2015) · Diabetes Care · doi:10.2337/dc15-0221 · Cited by 89
Socioeconomic status as an independent predictor of physiological biomarkers of cardiovascular disease: Evidence from NHANES
Muennig, P. A., Sohler, N., & Mahato, B. (2007) · Preventive Medicine · doi:10.1016/j.ypmed.2007.04.005 · Cited by 89
Inflammation and Cardiovascular Disease: The Future
Arnold, N., Lechner, K., Waldeyer, C., Shapiro, M. D., & Köenig, W. (2021) · European Cardiology Review · doi:10.15420/ecr.2020.50 · Cited by 93
Obesity, Dyslipidemias and Erectile Dysfunction: A Report of a Subcommittee of the Sexual Medicine Society of North America
Mulhall, J. P., Telöken, P., Brock, G. B., & Kim, E. (2006) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2006.00286.x · Cited by 87
Anti-Inflammatory and Antiatherogenic Role of BMP Receptor II in Endothelial Cells
Kim, C. W., Song, H. W., Kumar, S., Nam, D., Kwon, H., Chang, K. H., Son, D. J., Kang, D. W., Brodie, S. A., Weiss, D., et al. (2013) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.112.300287 · Cited by 90
Lipid-modifying therapy and attainment of cholesterol goals in Europe: the Return on Expenditure Achieved for Lipid Therapy (REALITY) study
Ganse, E. H. V., Laforest, L., Alemao, E., Davies, G., Gutkin, S. W., & Yin, D. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x59139 · Cited by 87
Chinese medicine tongxinluo significantly lowers serum lipid levels and stabilizes vulnerable plaques in a rabbit model
Chen, W. Q., Zhong, L., Zhang, L., Ji, X. P., Zhao, Y. X., Zhang, C., Jiang, H., Wu, Y. L., & Zhang, Y. (2009) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2009.04.009 · Cited by 87
Update on the NCEP ATP-III emerging cardiometabolic risk factors
Eckel, R. H., & Cornier, M. (2014) · BMC Medicine · doi:10.1186/1741-7015-12-115 · Cited by 96
C-reactive protein and cardiovascular disease: Weighing the evidence
Lowe, G. D. O., & Pepys, M. B. (2006) · Current Atherosclerosis Reports · doi:10.1007/s11883-006-0040-x · Cited by 87
The ratio of erythrocyte sedimentation rate to C-reactive protein is useful in distinguishing infection from flare in systemic lupus erythematosus patients presenting with fever
Littlejohn, E., Marder, W., Lewis, E., Francis, S., Jackish, J., McCune, W. J., & Somers, E. C. (2018) · Lupus · doi:10.1177/0961203318763732 · Cited by 87
IL1B gene promoter haplotype pairs predict clinical levels of interleukin-1β and C-reactive protein
Rogus, J. J., Beck, J. D., Offenbacher, S., Huttner, K. M., Iacoviello, L., Latella, M. C., de Gaetano, M., Wang, H., Kornman, K. S., & Duff, G. W. (2008) · Human Genetics · doi:10.1007/s00439-008-0488-6 · Cited by 86
Serum amyloid A: The “other” inflammatory protein
O’Brien, K. D., & Chait, A. (2006) · Current Atherosclerosis Reports · doi:10.1007/s11883-006-0066-0 · Cited by 87
Active Metabolite of Atorvastatin Inhibits Membrane Cholesterol Domain Formation by an Antioxidant Mechanism
Mason, R. P., Walter, M. F., Day, C. A., & Jacob, R. F. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m513000200 · Cited by 86
Moving Beyond JUPITER: Will Inhibiting Inflammation Reduce Vascular Event Rates?
Ridker, P. M. (2012) · Current Atherosclerosis Reports · doi:10.1007/s11883-012-0295-3 · Cited by 86
Self-citation
Clinical approach to the inflammatory etiology of cardiovascular diseases
Ruscica, M., Corsini, A., Ferri, N., Banach, M., & Sirtori, C. R. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104916 · Cited by 87
Circulating inflammatory and hemostatic biomarkers are associated with risk of myocardial infarction and coronary death, but not angina pectoris, in older men
Wannamethee, S. G., Whincup, P. H., Shaper, A. G., Rumley, A., LENNON, L. T., & Lowe, G. D. O. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03574.x · Cited by 84
Plaque Characteristics in Culprit Lesions and Inflammatory Status in Diabetic Acute Coronary Syndrome Patients
Hong, Y. J., Jeong, M. H., Choi, Y. H., Ko, J. S., Lee, M. G., Kang, W. Y., Lee, S. E., Kim, S. H., Park, K. H., Sim, D. S., et al. (2009) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2008.10.017 · Cited by 85
Effect of a plant stanol ester-containing spread, placebo spread, or Mediterranean diet on estimated cardiovascular risk and lipid, inflammatory and haemostatic factors
Athyros, V. G., Kakafika, A. I., Papageorgiou, A. A., Τζιόμαλος, Κ., Peletidou, A., Vosikis, C., Karagiannis, A. I., & Mikhailidis, D. P. (2009) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2009.08.014 · Cited by 85
Randomization to 6-month Mediterranean diet compared with a low-fat diet leads to improvement in Dietary Inflammatory Index scores in patients with coronary heart disease: the AUSMED Heart Trial
Mayr, H. L., Thomas, C. J., Tierney, A. C., Kucianski, T., George, E. S., Ruiz‐Canela, M., Hébert, J. R., Shivappa, N., & Itsiopoulos, C. (2018) · Nutrition Research · doi:10.1016/j.nutres.2018.04.006 · Cited by 87
Inflammatory Biomarkers in Stable Atherosclerosis
Kinlay, S., & Egido, J. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.09.014 · Cited by 84
Protective role of heme oxygenase-1 against inflammation in atherosclerosis
Durante, W. (2011) · Frontiers in bioscience · doi:10.2741/3860 · Cited by 83
Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials)
Murphy, S. A., Cannon, C. P., Wiviott, S. D., de Lemos, J. A., Blazing, M. A., McCabe, C. H., Califf, R. M., & Braunwald, E. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.04.053 · Cited by 82
Self-citation
Serum C-Reactive Protein and White Blood Cell Count in Morbidly Obese Surgical Patients
Chen, S.-B., Lee, Y.-C., Ser, K., Chen, J., Chen, S. C., Hsieh, H., & Lee, W. (2008) · Obesity Surgery · doi:10.1007/s11695-008-9619-3 · Cited by 82
La Aterosclerosis como enfermedad sistémica
Lahoz, C., & Mostaza, J. M. (2007) · Revista Española de Cardiología · doi:10.1157/13099465 · Cited by 82
Hepatic nuclear factor 1-α: inflammation, genetics, and atherosclerosis
Armendariz, A. D., & Krauss, R. M. (2009) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283295ee9 · Cited by 82
Increased Plasma Oxidized Phospholipid:Apolipoprotein B-100 Ratio With Concomitant Depletion of Oxidized Phospholipids From Atherosclerotic Lesions After Dietary Lipid-Lowering
Tsimikas, S., Aikawa, M., Miller, F. J., Miller, E. R., Torzewski, M., Lentz, S. R., Bergmark, C., Heistad, D. D., Libby, P., & Witztum, J. L. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000251501.86410.03 · Cited by 82
Irbesartan Treatment Reduces Biomarkers of Inflammatory Activity in Patients With Type 2 Diabetes and Microalbuminuria
Persson, F., Rossing, P. R., Hovind, P. H., Stehouwer, C. D. A., Schalkwijk, C. G., Tarnow, L., & Parving, H. (2006) · Diabetes · doi:10.2337/db06-0827 · Cited by 81
Postconditioning the Human Heart in Percutaneous Coronary Intervention
Xue, F., Yang, X., Zhang, B., Zhao, C., Song, J., Jiang, T., & Jiang, W. (2010) · Clinical Cardiology · doi:10.1002/clc.20796 · Cited by 81
Cardiovascular risk and rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion
Pham, T., Gossec, L., Constantin, A., Pavy, S., Bruckert, É., Cantagrel, A. G., Combe, B. G., Flipo, R., Goupille, P., Loët, X. L., et al. (2006) · Joint Bone Spine · doi:10.1016/j.jbspin.2006.01.014 · Cited by 81
Influence of Genetic Variation in the C‐Reactive Protein Gene on the Inflammatory Response During and After Acute Coronary Ischemia
Danik, J. S., Chasman, D. I., Cannon, C. P., Miller, D. T., Zee, R. Y. L., Kozłowski, P., Kwiatkowski, D. J., & Ridker, P. M. (2006) · Annals of Human Genetics · doi:10.1111/j.1469-1809.2006.00272.x · Cited by 80
Self-citation
Early Time to Benefit with Intensive Statin Treatment: Could It Be the Pleiotropic Effects?
Ray, K. K., & Cannon, C. P. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.06.027 · Cited by 80
Self-citation
A meta-analysis of the role of statins on renal outcomes in patients with chronic kidney disease. Is the duration of therapy important?
Nikolić, D., Banach, M., Nikfar, S., Salari, P., Mikhailidis, D. P., Toth, P. P., Abdollahi, M. R., Ray, K. K., Pencina, M. J., Małyszko, J., et al. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.08.060 · Cited by 80
Effect of atorvastatin on inflammation and outcome in patients with type 2 diabetes mellitus on hemodialysis
Krane, V., for the German Diabetes and Dialysis Study Investigators, Winkler, K., Drechsler, C., Lilienthal, J., März, W., & Wanner, C. (2008) · Kidney International · doi:10.1038/ki.2008.484 · Cited by 79
High-sensitivity C-reactive protein as a risk assessment tool for cardiovascular disease
Yeh, E. T. H. (2005) · Clinical Cardiology · doi:10.1002/clc.4960280905 · Cited by 81
Coronary Spasm is Associated With Chronic Low-Grade Inflammation
Itoh, T., Mizuno, Y., Harada, E., Yoshimura, M., Ogawa, H., & Yasue, H. (2007) · Circulation Journal · doi:10.1253/circj.71.1074 · Cited by 79
The role of inflammation in cardiovascular diseases: the predictive value of neutrophil–lymphocyte ratio as a marker in peripheral arterial disease
Paquissi, F. C. (2016) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s107635 · Cited by 80
Proapoptotic, Antimigratory, Antiproliferative, and Antiangiogenic Effects of Commercial C-Reactive Protein on Various Human Endothelial Cell Types In Vitro
Liu, C., Wang, S., Deb, A., Nath, K. A., Katušić, Z. S., McConnell, J. P., & Caplice, N. M. (2005) · Circulation Research · doi:10.1161/01.res.0000174612.90094.fd · Cited by 82
Epidemiology of Dialysis Patients and Heart Failure Patients
Kalantar‐Zadeh, K., Abbott, K. C., Kronenberg, F., Anker, S. D., Horwich, T. B., & Fonarow, G. C. (2006) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2005.09.005 · Cited by 80
Blocking Interleukin-1 as a Novel Therapeutic Strategy for Secondary Prevention of Cardiovascular Events
Abbate, A., Tassell, B. W. V., & Biondi‐Zoccai, G. (2012) · BioDrugs · doi:10.1007/bf03261881 · Cited by 78
Supplementation with orange and blackcurrant juice, but not vitamin E, improves inflammatory markers in patients with peripheral arterial disease
Dalgård, C., Nielsen, F., Morrow, J. D., Enghusen-Poulsen, H., Jonung, T., Hørder, M., & de Maat, M. P. M. (2008) · British Journal Of Nutrition · doi:10.1017/s0007114508995660 · Cited by 78
Lipoprotein(a) is linked to atherothrombosis and aortic valve stenosis independent of C-reactive protein
Thomas, P. E., Vedel‐Krogh, S., Kamstrup, P. R., & Nordestgaard, B. G. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad055 · Cited by 82
C-reactive protein stimulates superoxide anion release and tissue factor activity in vivo
Devaraj, S., Dasu, M. R. K., Singh, U. S., Rao, L. V. M., & Jialal, I. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.05.060 · Cited by 77
Fenofibrate Reduces Atherogenesis in ApoE*3Leiden Mice
Kooistra, T., Verschuren, L., der Weij, J. D. V.-V., Köenig, W., Toet, K. H., Princen, H. M. G., & Kleemann, R. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000238348.05028.14 · Cited by 80
Modified Lipoproteins Induce Arterial Wall Inflammation During Atherogenesis
Lorey, M. B., Öörni, K., & Kovanen, P. T. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.841545 · Cited by 82
Individual Variation of Scavenger Receptor Expression in Human Macrophages with Oxidized Low-Density Lipoprotein Is Associated with a Differential Inflammatory Response
Martín‐Fuentes, P., Civeira, F., Recalde, D., García-Otín, A. L., Jarauta, E., Marzo, I., & Cenarro, A. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.5.3242 · Cited by 78
Ezetimibe reduces plaque inflammation in a rabbit model of atherosclerosis and inhibits monocyte migration in addition to its lipid‐lowering effect
Gómez‐Garré, D., Muñoz‐Pacheco, P., Gonzalez-Rubio, M., Aragoncillo, P., Granados, R., & Fernández‐Cruz, A. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2008.00091.x · Cited by 77
Postprandial Dysmetabolism: the Missing Link Between Diabetes and Cardiovascular Events?
Bell, D. S. H., O’Keefe, J. H., & Jellinger, P. S. (2008) · Endocrine Practice · doi:10.4158/ep.14.1.112 · Cited by 77
Statins in community acquired pneumonia: Evidence from experimental and clinical studies
Chalmers, J. D., Short, P. M., Mandal, P., Akram, A. R., & Hill, A. T. (2010) · Respiratory Medicine · doi:10.1016/j.rmed.2010.04.005 · Cited by 78
Investigation of the effect of Interleukin-1 receptor antagonist (IL-1ra) on markers of inflammation in non-ST elevation acute coronary syndromes (The MRC-ILA-HEART Study)
Crossman, D. C., Morton, A. C., Gunn, J. P., Greenwood, J. P., Hall, A. S., Fox, K. A. A., Lucking, A. J., Flather, M. D., Lees, B., & Foley, C. E. (2008) · Trials · doi:10.1186/1745-6215-9-8 · Cited by 77
C-Reactive Protein as a Risk Predictor
Albert, M. A., & Ridker, P. M. (2006) · Circulation · doi:10.1161/circulationaha.106.613570 · Cited by 77
Self-citation
Metabolic Syndrome, Inflammation, and Risk of Symptomatic Peripheral Artery Disease in Women
Conen, D., Rexrode, K. M., Creager, M. A., Ridker, P. M., & Pradhan, A. D. (2009) · Circulation · doi:10.1161/circulationaha.109.863092 · Cited by 77
Self-citation
The effect of BMS-582949, a P38 mitogen-activated protein kinase (P38 MAPK) inhibitor on arterial inflammation: A multicenter FDG-PET trial
Emami, H., Vucic, E., Subramanian, S. S., Abdelbaky, A., Fayad, Z. A., Du, S., Roth, E. M., Ballantyne, C. M., Mohler, E. R., Farkouh, M. E., et al. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.03.039 · Cited by 77
Persistent Activation of Nuclear Factor Kappa-B Signaling Pathway in Patients With Unstable Angina and Elevated Levels of C-Reactive Protein
Liuzzo, G., Santamaria, M., Biasucci, L. M., Narducci, M., Colafrancesco, V., Porto, A., Brugaletta, S., Pinnelli, M., Rizzello, V., Maseri, A., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.07.071 · Cited by 78
Early intensive statin treatment for six months improves long-term clinical outcomes in patients with acute coronary syndrome (Extended-ESTABLISH trial): A follow-up study
Dohi, T., Miyauchi, K., Okazaki, S., Yokoyama, T., Yanagisawa, N., Tamura, H., Kojima, T., Yokoyama, K., Kurata, T., & Daida, H. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.12.001 · Cited by 76
Has the time finally come to measure hsCRP universally in primary and secondary cardiovascular prevention?
Ridker, P. M., Köenig, W., Kastelein, J. J. P., Mach, F., & Lüscher, T. F. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy723 · Cited by 80
Self-citation
Functional Foods: Opportunities & Challenges
Clydesdale, F. M. (2004) · ScholarWorks@UMassAmherst (University of Massachusetts Amherst) · Cited by 85
C-Reactive Protein, Diastolic Dysfunction, and Risk of Heart Failure in Patients with Coronary Disease: Heart and Soul Study
Williams, E. S., Shah, S. J., Ali, S., Na, B. Y., Schiller, N. B., & Whooley, M. A. (2007) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2007.11.003 · Cited by 75
Statins, especially atorvastatin, may favorably influence clinical presentation and biochemical progression-free survival after brachytherapy for clinically localized prostate cancer
Moyad, M. A., Merrick, G. S., Butler, W. M., Wallner, K. E., Galbreath, R. W., Kurko, B. S., & Adamovich, E. (2005) · Urology · doi:10.1016/j.urology.2005.08.053 · Cited by 75
Prevention of Atrial Fibrillation With 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors
Adam, O., Neuberger, H., Böhm, M., & Laufs, U. (2008) · Circulation · doi:10.1161/circulationaha.107.760892 · Cited by 73
Proteína C reativa de alta sensibilidade como biomarcador de risco na doença coronária
Silva, D., & de Lacerda, A. P. (2012) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2012.02.018 · Cited by 74
High-Sensitivity C-Reactive Protein as an Associate of Clinical Subsets and Organ Damage in Systemic Lupus Erythematosus
Lee, S., Singh, S., Link, K., & Petri, M. (2008) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2007.09.005 · Cited by 75
Impact of C-reactive protein and fibrinogen on cardiovascular prognosis in patients with stable angina pectoris: the AtheroGene study
Sinning, J., Bickel, C., Messow, C., Schnabel, R. B., Lubos, E., Rupprecht, H.-J., Espinola–Klein, C., Lackner, K. J., Tiret, L., Münzel, T. F., et al. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl362 · Cited by 75
Clinical Application of C-Reactive Protein Across the Spectrum of Acute Coronary Syndromes
Scirica, B. M., Morrow, D. A., Cannon, C. P., de Lemos, J. A., Murphy, S. A., Sabatine, M. S., Wiviott, S. D., Rifai, N., McCabe, C. H., Braunwald, E., et al. (2007) · Clinical Chemistry · doi:10.1373/clinchem.2007.087957 · Cited by 75
Self-citation
Prospects for Personalized Cardiovascular Medicine
Ginsburg, G. S., Donahue, M., & Newby, L. K. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.06.075 · Cited by 72
Coronary Stenting and Inflammation
Gaspardone, A., & Versaci, F. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.09.064 · Cited by 77
Specific Serotonin Reuptake Inhibition in Major Depressive Disorder Adversely Affects Novel Markers of Cardiac Risk
Dawood, T., Lambert, É., Barton, D., Laude, D., Elghozi, J., Esler, M., Haikerwal, D., Kaye, D. M., Hotchkin, E., & Lambert, G. W. (2007) · Hypertension Research · doi:10.1291/hypres.30.285 · Cited by 77
Why Colchicine Should Be Considered for Secondary Prevention of Atherosclerosis: An Overview
Nidorf, S. M., & Thompson, P. L. (2018) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.11.016 · Cited by 78
The Year in Non–ST-Segment Elevation Acute Coronary Syndrome
Giugliano, R. P., & Braunwald, E. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.09.016 · Cited by 72
Association of statin use with cognitive decline in elderly African Americans
Szwast, S. J., Hendrie, H. C., Lane, K. A., Gao, S., Taylor, S., Unverzagt, F. W., Murrell, J. R., Deeg, M. A., Ogunniyi, A. O., Farlow, M. R., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000279333.77404.d7 · Cited by 74
C‑reactive protein and cardiovascular disease: From animal studies to the clinic (Review)
Fu, Y., Wu, Y., & Liu, E. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.8840 · Cited by 77
Cardiac rehabilitation and exercise therapy in the elderly: Should we invest in the aged?
Menezes Arthur, R., Lavie, C. J., Richard, V. M., Arena, R. A., & Timothy, S. (2012) · 老年心脏病学杂志：英文版 · doi:10.3724/sp.j.1263.2012.00068 · Cited by 72
Plaque Stabilization: Can We Turn Theory into Evidence?
Libby, P., & Sasiela, W. J. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.09.017 · Cited by 72
Statins and biomarkers of inflammation
Devaraj, S., Rogers, J., & Jialal, I. (2007) · Current Atherosclerosis Reports · doi:10.1007/bf02693938 · Cited by 74
Fibrinogen and Albumin Levels and Risk of Atrial Fibrillation in Men and Women (the Copenhagen City Heart Study)
Mukamal, K. J., Tolstrup, J. S., Friberg, J., Grønbæk, M., & Jensen, G. B. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.01.067 · Cited by 73
Effects of CRP infusion on endothelial function and coagulation in normocholesterolemic and hypercholesterolemic subjects
Bisoendial, R. J., Kastelein, J. J. P., Peters, S. L. M., Levels, J. H. M., Birjmohun, R. S., Rotmans, J. I., Hartman, D., Meijers, J. C. M., Levi, M. M., & Stroes, E. S. G. (2007) · Journal of Lipid Research · doi:10.1194/jlr.p600014-jlr200 · Cited by 74
Influence of atorvastatin on coronary calcifications and myocardial perfusion defects in systemic lupus erythematosus patients: a prospective, randomized, double-masked, placebo-controlled study
Płazak, W., Gryga, K., Dziedzic‐Oleksy, H., Pająk, L. T., Konieczyńska, M., Podolec, P. S., & Musiał, J. (2011) · Arthritis Research & Therapy · doi:10.1186/ar3402 · Cited by 73
Disodium Disuccinate Astaxanthin (Cardax) Attenuates Complement Activation and Reduces Myocardial Injury following Ischemia/Reperfusion
Lauver, A. A., Lockwood, S. F., & Lucchesi, B. R. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.087114 · Cited by 73

Authors: Ridker, P. M., Cannon, C. P., Morrow, D., Rifai, N., Rose, L. M., McCabe, C. H., Pfeffer, M. A., & Braunwald, E.
Affiliations: Brigham and Women's Hospital (US)
ORCID: Ridker, Paul M
Cannon, Christopher P.
Morrow, David
Rifai, Nader
Rose, Lynda M.
Pfeffer, Marc A.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2005-01-06
Volume: 352
Issue: 1
Pages: 20-28
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa042378
OpenAlex: W2118154631
Cited by: 2,292
References: 28
Citations by year: 2026: 32 · 2025: 46 · 2024: 47 · 2023: 52 · 2022: 70 · 2021: 58 · 2020: 74 · 2019: 64 · 2018: 72 · 2017: 54 · 2016: 78 · 2015: 62 · 2014: 67 · 2013: 93 · 2012: 88
FWCI: 282.76
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Keywords: C-reactive protein, statin therapy, LDL cholesterol, atorvastatin, pravastatin, acute coronary syndrome, reinfarction, coronary death, cardiovascular risk, lipid-lowering targets
MeSH terms: Atorvastatin, Gatifloxacin, Anticholesteremic Agents, C-Reactive Protein, Coronary Disease, Female, Heptanoic Acids, Humans, Cholesterol, LDL, Male, Middle Aged, Myocardial Infarction, Pyrroles, Risk Factors, Biomarkers, Incidence, Proportional Hazards Models, Pravastatin, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Fluoroquinolones, Secondary Prevention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

C-Reactive Protein Levels and Outcomes after Statin Therapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks